Does Pharmacological Treatment Reduce the Incidence of Lower Urinary Tract Symptoms (LUTS) after Transobturator Sling?
Table 4
The evolution of nocturia in the course of the study.
Variable
Baseline n (%) [B]
Week 1 n (%) [W1]
Week 6 n (%) [W6]
Statistical analyses inside each group
Control group (n=110) C
16 (14.5)
18 (16.4)
8 (7.3)
B vs.W1, NS B vs. W6, NS W1 vs. W6, p <0.05
Treatment group 1 (10 mg of solifenacin) (n=114) S
19 (16.7)
17 (14.9)
5 (4.4)
B vs.W1, NS B vs. W6, p <0.005 W1 vs. W6, p <0.01
Treatment group 2 (50 mg of mirabegron) (n=104) M
20 (19.2)
17 (16.3)
10 (9.6)
B vs.W1, NS B vs. W6, p <0.05 W1 vs. W6, NS
Baseline: C vs. S (NS); C vs. M (NS); S vs. M (NS). Week 1: C vs. S (NS); C vs. M (NS); S vs. M (NS). Week 6: C vs. S (NS); C vs. M (NS); S vs. M (NS).
